Muscle-directed anti-Aβ Single-Chain Antibody Delivery Via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model

Journal of Molecular Neuroscience

Volumn 49, Issue 2, 2013, Pages 277-288

  Yang, Junling ^a   Pattanayak, Abhinandan ^a   Song, Min ^a,b   Kou, Jinghong ^a   Taguchi, Hiroaki ^c   Paul, Sudhir ^c   Ponnazhagan, Selvarangan ^d   Lalonde, Robert ^e   Fukuchi, Ken Ichiro ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b JIUJIANG UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

Adeno associated virus; Alzheimer's disease; Amyloid; Cerebrospinal fluid; Single chain antibody

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CEREBROSPINAL FLUID; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOUSE; NEOCORTEX; NONHUMAN; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; SEROTYPE; VIRAL GENE THERAPY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE TARGETING; GENETIC THERAPY; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED C57BL; MUSCLES; SINGLE-CHAIN ANTIBODIES;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84875698008     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9877-3     Document Type: Article

References (50)

1. Bard F, Cannon C, Barbour R et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916-919 (Pubitemid 30644751)
2. Bird RE, Hardman KD, Jacobson JW et al (1988) Single-chain antigen-binding proteins. Science 242(4877):423-426
3. Check E (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415(6871):462 (Pubitemid 34130572)
4. Cohn EF, Zhuo J, Kelly ME, Chao HJ (2007) Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer. J Thromb Haemost 5(6):1227-1236 (Pubitemid 46902125)
5. Cummings JL (2011) Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 7(3):e13-e44
6. -/- knock-out mice. J Neurosci 23(24):8532-8538 (Pubitemid 37158753)
7. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15):8850-8855 (Pubitemid 32678116)
8. DeMattos RB, Bales KR, Parsadanian M et al (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81(2):229-236 (Pubitemid 34809348)
9. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64(3):343-349 (Pubitemid 46425688)
10. Flood DG, Marek GJ, Williams M (2011) Developing predictive CSF biomarkers - a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol 81(12):1422-1434
11. Fukuchi KI, Accavitti-Loper M, Kim HD et al (2006a) Amelioration of amyloid load by anti-A[beta] single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344:79-86
12. Fukuchi KI, Tahara K, Kim HD et al (2006b) Anti-Aβ single chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 23:502-511 (Pubitemid 44234087)
13. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29(6):1362-1367 (Pubitemid 20063361)
14. Grill JD, Cummings JL (2010) Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 10(5):711-728
15. Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7(6):839-850 (Pubitemid 36790261)
16. Guillemin GJ, Brew BJ (2004) Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 75(3):388-397 (Pubitemid 38316367)
17. Hampel H, Wilcock G, Andrieu S et al (2011) Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95(4):579-593
18. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228-234 (Pubitemid 43238346)
19. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52(1):3-13 (Pubitemid 44472602)
20. Huston JS, Mudgett-Hunter M, Tai MS et al (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46-88
21. Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9(1):119-128
22. Jankowsky JL, Fadale DJ, Anderson J et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159-170 (Pubitemid 38111354)
23. Janus C, Pearson J, McLaurin J et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408(6815):979-982 (Pubitemid 32101644)
24. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698-712
25. Kasturirangan S, Sierks M (2010) Targeted hydrolysis of beta-amyloid with engineered antibody fragment. Curr Alzheimer Res 7(3):214-222
26. Kelly ME, Zhuo J, Bharadwaj AS, Chao H (2009) Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther 17(5):857-863
27. Kou J, Kim HD, Pattanyak A et al (2011) Anti-Abeta single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer mouse model. J Alzheimers Dis 27(1):23-28
28. Lai AY, McLaurin J (2012) Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Futur Neurol 7(2):165-176
29. Levites Y, Das P, Price RW et al (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116(1):193-201 (Pubitemid 43121804)
30. McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5(3):333-338 (Pubitemid 40895017)
31. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12(5):341-355
32. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269(1):54-63
33. Morgan D, Diamond DM, Gottschall PE et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408(6815):982-985 (Pubitemid 32101645)
34. Nicoll JA, Barton E, Boche D et al (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11):1040-1048 (Pubitemid 44684661)
35. Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46-54 (Pubitemid 36818745)
36. Panza F, Frisardi V, Imbimbo BP et al (2010) Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2(6):767-782
37. Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461(7266):916-922
38. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ (2010) Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 18(8):1471-1481
39. Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173-177 (Pubitemid 29327547)
40. Shoji M (2011) Biomarkers of the dementia. Int J Alzheimers Dis 2011:564321
41. Siemers ER, Friedrich S, Dean RA et al (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33(2):67-73
42. Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer's disease? Neurobiol Aging 23(6):1001-1008 (Pubitemid 35447780)
43. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94(8):4109-4112 (Pubitemid 27180507)
44. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44):29615-29619
45. Verma R, Boleti E, George AJ (1998) Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods 216(1-2):165-181 (Pubitemid 28440386)
46. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW (2005) Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105(11):4226-4234 (Pubitemid 40720767)
47. Wang YJ, Gao CY, Yang M et al (2010) Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 24(8):1281-1293
48. Wang YJ, Pollard A, Zhong JH et al (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30(3):364-376
49. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89(4):807-811 (Pubitemid 38684728)
50. Zolotukhin S, Potter M, Zolotukhin I et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28(2):158-167 (Pubitemid 35341079)